What is the appropriate evaluation and management for a patient with low serum iron, high ferritin, neutropenia, and leukopenia?

Evaluation and Management of Low Iron, High Ferritin, Neutropenia, and Leukopenia

This constellation of findings—low serum iron with high ferritin, neutropenia, and leukopenia—should prompt immediate evaluation for myelodysplastic syndrome (MDS), as this represents a classic presentation of functional iron deficiency in the setting of bone marrow dysfunction, and requires bone marrow examination for definitive diagnosis. 1

Immediate Diagnostic Workup

Essential Laboratory Studies

• Complete blood count with differential to quantify the degree of neutropenia and assess for other cytopenias (anemia, thrombocytopenia) that would strongly suggest MDS 1
• Peripheral blood smear to evaluate for dysplastic features in circulating cells 1
• Transferrin saturation (TSAT) to confirm functional iron deficiency (typically TSAT <20% with ferritin >100-200 ng/mL) 2, 3
• Reticulocyte count to assess bone marrow response 2

Bone Marrow Evaluation

• Bone marrow aspirate and biopsy are mandatory when neutropenia occurs with high ferritin and low iron, as this pattern strongly suggests MDS with iron overload 1
• Morphologic review should assess for dysplasia in multiple cell lines and blast percentage 1
• Cytogenetic analysis and molecular testing should be performed to risk-stratify MDS if diagnosed 1

Alternative Diagnoses to Exclude

While MDS is the primary concern, systematically exclude:

• Chronic infections (hepatitis B/C, HIV, CMV) through serologic testing 4
• Autoimmune disorders (lupus, rheumatoid arthritis) via ANA, anti-DNA antibodies, rheumatoid factor 4
• Thyroid dysfunction with free T4 and TSH 4
• Vitamin deficiencies (B12, folate) that can cause cytopenias 4
• Drug-induced neutropenia through careful medication history 4

Understanding the Iron Paradox

High ferritin with low serum iron represents functional iron deficiency, where iron is sequestered in storage forms but unavailable for erythropoiesis 2, 3. This occurs in:

• MDS and bone marrow disorders where ineffective erythropoiesis leads to iron accumulation 1
• Chronic inflammation where elevated hepcidin blocks iron release from stores 2
• Transfusion-dependent states causing iron overload 1

The ferritin level is particularly unreliable in inflammatory states and should not be interpreted in isolation 5. In MDS patients, ferritin >1000 ng/mL indicates significant iron overload requiring chelation therapy 1.

Management Based on Diagnosis

If MDS is Confirmed

Risk stratification using IPSS or WPSS scores determines treatment intensity 1:

• High-risk disease (IPSS INT-2/High or WPSS High/Very High):

  • Allogeneic hematopoietic stem cell transplant (HSCT) if transplant candidate with available donor 1
  • Azacitidine (preferred, category 1 evidence) or decitabine if not transplant candidate 1
  • High-intensity chemotherapy as bridge to transplant 1

• Lower-risk disease with severe cytopenias:

  • Consider HSCT if unresponsive to standard therapy 1
  • Supportive care with transfusions and growth factors 1

Iron Management in MDS Context

• Iron chelation therapy is indicated after >20-30 RBC transfusions or when ferritin >1000 ng/mL, particularly for transplant candidates 1
• Options include deferoxamine (subcutaneous) or deferasirox (oral) 1
• Goal is to reduce ferritin to <1000 ng/mL to minimize organ damage from iron overload 1
• Do NOT administer IV iron when ferritin is already elevated, as this worsens iron overload 3

Neutropenia Management

• G-CSF or GM-CSF should be considered for recurrent or resistant infections in neutropenic patients, though not recommended for routine prophylaxis 1
• Monitor platelet counts when using growth factors 1
• Use leuko-reduced, irradiated blood products for transfusion in transplant candidates 1
• CMV-negative products for CMV-negative transplant candidates 1

Critical Pitfalls to Avoid

Do Not Treat Iron Deficiency Without Diagnosis

Never administer IV iron when ferritin is elevated (>500 ng/mL), as this increases infection risk and worsens iron overload 3, 6. One study demonstrated that hemodialysis patients with functional iron deficiency (high ferritin, low TSAT) who received IV iron showed marked impairment of neutrophil function, increasing infection risk 6.

Do Not Miss Underlying Malignancy

The combination of cytopenias with iron dysregulation mandates bone marrow evaluation—delaying this diagnosis allows MDS to progress toward acute leukemia 1. In RAEB subtypes, 25-55% transform to AML within one year 1.

Consider Rare Iron-Responsive Neutropenia

In 2-2.1% of cases, neutropenia may actually be caused by iron deficiency itself 7, 4. One case report documented complete resolution of 16-year chronic idiopathic neutropenia after 2.5 months of oral iron supplementation 7. However, this diagnosis requires:

• Low ferritin (<100 ng/mL), not high ferritin 7, 4
• Exclusion of other causes through systematic evaluation 4
• Trial of oral iron supplementation for 1-3 months 3, 7

This scenario does NOT apply to your patient with high ferritin, where iron supplementation would be contraindicated.

Monitor for Infection Risk

Withhold IV iron during active infections, as iron promotes microbial growth 3. Patients with functional iron deficiency receiving IV iron therapy show impaired neutrophil phagocytosis and intracellular killing 6.

Follow-Up Monitoring

Once diagnosis is established:

• Hemoglobin monthly once stable 3
• Ferritin and TSAT every 3 months to monitor iron status 3
• Serial CBCs to track neutropenia and assess for progression 8
• Bone marrow reassessment if clinical deterioration or blast count concerns 1